ASCO 2014:结节型病变是口腔粘膜黑色素瘤的危险信号

2014-05-31 ruanancy 译 医学论坛网

摘要号:#6058 第一作者:郭伟,上海交通大学医学院附属第九人民医院口腔颌面外科 背景:口腔粘膜黑色素瘤(OMM)经常转移至颈部淋巴结。虽然为评估颈淋巴结清除术治疗OMM的疗效已进行了大量研究,但该领域依然存在相当多的争议。 方法:对1998年1月至2012年7月期间254 例OMM患者的临床特点、治疗和预后情况进行回顾性分析;并进行多变量分析,以确定与总生

摘要号:#6058

第一作者:郭伟,上海交通大学医学院附属第九人民医院口腔颌面外科

背景:口腔粘膜黑色素瘤(OMM)经常转移至颈部淋巴结。虽然为评估颈淋巴结清除术治疗OMM的疗效已进行了大量研究,但该领域依然存在相当多的争议。

方法:对1998年1月至2012年7月期间254 例OMM患者的临床特点、治疗和预后情况进行回顾性分析;并进行多变量分析,以确定与总生存期(OS)相关的变量。

结果:肿瘤直径大于4cm(P = 0.01)和结节型(P <0.0001)是OS的两个独立预后因素。与黄斑黑色素瘤患者相比,结节型黑色素瘤患者更可能发生远端转移(P<0.0001)。 164例患者(65%)发生了CLN转移。多变量分析显示,预防性颈淋巴结清除术是cN0期结节型黑色素瘤患者OS的一个独立有利因素(P=0.0016);而根治性颈清除术(P=0.03)是CLN阳性患者的一个独立有利因素。行功能性颈清除术的患者更可能发生颈部黑色素瘤复发(P <0.001)。

结论:结节型病变是OMM的一种危险信号。明智之举是,对cN0期结节型黑色素瘤患者进行预防性颈淋巴结清除术。建议对cN0期黄斑黑色素瘤患者进行密切观察,而对CLN阳性患者应行根治性颈切除术。

研究链接:Neck dissection for oral mucosal melanoma: Caution of nodular lesion. (Abstract 6058)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1680241, encodeId=89ab1680241c2, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Fri Jan 16 19:38:00 CST 2015, time=2015-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060481, encodeId=661d2060481c3, content=<a href='/topic/show?id=6b5e36e72d8' target=_blank style='color:#2F92EE;'>#危险信号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36772, encryptionId=6b5e36e72d8, topicName=危险信号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Tue Apr 21 22:38:00 CST 2015, time=2015-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938326, encodeId=37c2193832614, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Dec 08 08:38:00 CST 2014, time=2014-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690944, encodeId=8ddb169094423, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Fri Apr 24 04:38:00 CST 2015, time=2015-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558657, encodeId=5305155865ebd, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Mon Jun 02 12:38:00 CST 2014, time=2014-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564666, encodeId=b1f91564666ce, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Mon Jun 02 12:38:00 CST 2014, time=2014-06-02, status=1, ipAttribution=)]
    2015-01-16 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1680241, encodeId=89ab1680241c2, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Fri Jan 16 19:38:00 CST 2015, time=2015-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060481, encodeId=661d2060481c3, content=<a href='/topic/show?id=6b5e36e72d8' target=_blank style='color:#2F92EE;'>#危险信号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36772, encryptionId=6b5e36e72d8, topicName=危险信号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Tue Apr 21 22:38:00 CST 2015, time=2015-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938326, encodeId=37c2193832614, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Dec 08 08:38:00 CST 2014, time=2014-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690944, encodeId=8ddb169094423, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Fri Apr 24 04:38:00 CST 2015, time=2015-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558657, encodeId=5305155865ebd, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Mon Jun 02 12:38:00 CST 2014, time=2014-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564666, encodeId=b1f91564666ce, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Mon Jun 02 12:38:00 CST 2014, time=2014-06-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1680241, encodeId=89ab1680241c2, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Fri Jan 16 19:38:00 CST 2015, time=2015-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060481, encodeId=661d2060481c3, content=<a href='/topic/show?id=6b5e36e72d8' target=_blank style='color:#2F92EE;'>#危险信号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36772, encryptionId=6b5e36e72d8, topicName=危险信号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Tue Apr 21 22:38:00 CST 2015, time=2015-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938326, encodeId=37c2193832614, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Dec 08 08:38:00 CST 2014, time=2014-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690944, encodeId=8ddb169094423, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Fri Apr 24 04:38:00 CST 2015, time=2015-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558657, encodeId=5305155865ebd, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Mon Jun 02 12:38:00 CST 2014, time=2014-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564666, encodeId=b1f91564666ce, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Mon Jun 02 12:38:00 CST 2014, time=2014-06-02, status=1, ipAttribution=)]
    2014-12-08 quxin068
  4. [GetPortalCommentsPageByObjectIdResponse(id=1680241, encodeId=89ab1680241c2, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Fri Jan 16 19:38:00 CST 2015, time=2015-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060481, encodeId=661d2060481c3, content=<a href='/topic/show?id=6b5e36e72d8' target=_blank style='color:#2F92EE;'>#危险信号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36772, encryptionId=6b5e36e72d8, topicName=危险信号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Tue Apr 21 22:38:00 CST 2015, time=2015-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938326, encodeId=37c2193832614, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Dec 08 08:38:00 CST 2014, time=2014-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690944, encodeId=8ddb169094423, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Fri Apr 24 04:38:00 CST 2015, time=2015-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558657, encodeId=5305155865ebd, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Mon Jun 02 12:38:00 CST 2014, time=2014-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564666, encodeId=b1f91564666ce, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Mon Jun 02 12:38:00 CST 2014, time=2014-06-02, status=1, ipAttribution=)]
    2015-04-24 guoyibin
  5. [GetPortalCommentsPageByObjectIdResponse(id=1680241, encodeId=89ab1680241c2, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Fri Jan 16 19:38:00 CST 2015, time=2015-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060481, encodeId=661d2060481c3, content=<a href='/topic/show?id=6b5e36e72d8' target=_blank style='color:#2F92EE;'>#危险信号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36772, encryptionId=6b5e36e72d8, topicName=危险信号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Tue Apr 21 22:38:00 CST 2015, time=2015-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938326, encodeId=37c2193832614, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Dec 08 08:38:00 CST 2014, time=2014-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690944, encodeId=8ddb169094423, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Fri Apr 24 04:38:00 CST 2015, time=2015-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558657, encodeId=5305155865ebd, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Mon Jun 02 12:38:00 CST 2014, time=2014-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564666, encodeId=b1f91564666ce, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Mon Jun 02 12:38:00 CST 2014, time=2014-06-02, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1680241, encodeId=89ab1680241c2, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Fri Jan 16 19:38:00 CST 2015, time=2015-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060481, encodeId=661d2060481c3, content=<a href='/topic/show?id=6b5e36e72d8' target=_blank style='color:#2F92EE;'>#危险信号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36772, encryptionId=6b5e36e72d8, topicName=危险信号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Tue Apr 21 22:38:00 CST 2015, time=2015-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938326, encodeId=37c2193832614, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Dec 08 08:38:00 CST 2014, time=2014-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690944, encodeId=8ddb169094423, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Fri Apr 24 04:38:00 CST 2015, time=2015-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558657, encodeId=5305155865ebd, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Mon Jun 02 12:38:00 CST 2014, time=2014-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564666, encodeId=b1f91564666ce, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Mon Jun 02 12:38:00 CST 2014, time=2014-06-02, status=1, ipAttribution=)]

相关资讯

ASCO 2014:亚洲进展期肝癌患者口服c-Met抑制剂MSC2156119J单药与索拉非尼比较的Ib/II期试验

摘要号:#TPS4151 第一作者:秦叔逵,中国人民解放军81医院 标题:肝功能Child-Pugh A级,MET阳性(MET+)的亚洲进展期肝细胞癌(HCC)患者中口服c-Met抑制剂MSC2156119J单药治疗与索拉非尼比较的多中心随机Ib/II期试验 背景:HCC患者(pts)预后较差,有效治疗手段有限,在占80%HCC负担的亚洲尤其如此。一项I期试验

ASCO 2014:阿帕替尼治疗中国进展期肝癌患者的II期研究

标题:中国进展期肝细胞癌患者中应用阿帕替尼的II期随机开放性试验 摘要号:#4019 第一作者:秦叔逵,中国人民解放军81医院 背景:晚期肝细胞癌(HCC)是全球癌症死亡的第三大常见原因。阿帕替尼是一种新型口服的血管内皮生长因子受体-2多激酶抑制剂。本文报告了阿帕替尼一线治疗中国进展期HCC患者的II期临床研究结果。 方法: 这是一项多中心、随机、开放

ASCO 2014:尼妥珠单抗+紫杉醇、顺铂一线治疗食管鳞癌更优

尼妥珠单抗联合紫杉醇及顺铂用作食管鳞状细胞癌的一线治疗:单中心前瞻性临床试验的最终结果 摘要号:#4070 第一作者:陆明,北京大学肿瘤医院消化肿瘤内科 背景: 尼妥珠单抗(N)是一种人源化抗EGFR单克隆抗体。我们进行了一项前瞻性单组开放性II期研究评价紫衫醇(T)/顺铂(C)/尼妥珠单抗(N)作为进展期ESCC一线治疗的疗效和安全性。  方法:病

ASCO 2014:韩宝惠谈第三代EGFR抑制剂对NSCLC的疗效

题目:EGFR抑制剂耐药的非小细胞肺癌(NSCLC)患者中应用突变选择性EGFR抑制剂AZD9291的临床活性(Clinical activity of the mutant selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor resistant non-small cell lung cancer (NS

ASCO 2014:局部进展期食管癌术前新辅助放化疗与单纯手术比较的III期试验

局部进展期食管鳞状细胞癌中术前新辅助放化疗与单纯手术比较的III期临床试验 摘要号:#Tps4146 第一作者:杨弘,中山大学附属肿瘤医院胸外科 背景:手术是食管鳞状细胞癌(ESCC)的主要治疗,不过局部进展期ESCC患者的预后相当差。术前放化疗后手术治疗似乎有望改善ESCC的生存。不过,不同研究的结果并不一致。我们进行了一项III期临床试验来评价多学科治疗对

ASCO 2014:江泽飞:早期乳腺癌双靶向预防复发研究(ALTTO研究)

“不大不小的好消息”:早期乳腺癌双靶向预防复发研究题目:早期HER2阳性乳腺癌中对比拉帕替尼(L)单药,曲妥珠单抗(T)单药,二者序贯(T→L)或联合(T+L)抗HER2辅助治疗1年的Ⅲ期ALTTO试验首次结果(First results from the phase Ⅲ ALTTO trial comparing one year of anti-HER2 therapy with la